Study Protocol
Published on 04 Apr 2022
Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
in Nephrology
Frontiers in Medicine
doi 10.3389/fmed.2022.783387
- 4,831 views
- 6 citations
